Skip to main content

Table 3 Subgroup analysis of BANCR expression and overall survival (OS) in cancer patients

From: High BANCR expression is associated with worse prognosis in human malignant carcinomas: an updated systematic review and meta-analysis

  No. of studies No. of patients Pooled HR (95% CI) Heterogeneity
       Fixed Random I2(%) P-value
Overall survival 10 1151 1.56 (1.35–1.81) 1.60 (1.19–2.15) 60 0.008
Cancer type       
Digestive system 4 551 1.87 (1.40–2.50) 1.94 (1.38–2.73) 17 0.31
GC 1 184 1.51 (1.03–2.23) 1.51 (1.03–2.23)
ESCC 1 142 2.24 (1.05–4.76) 2.24 (1.05–4.76)
HCC 1 109 4.24 (1.32–13.61) 4.24 (1.32–13.61)
CRC 1 116 2.24 (1.22–4.11) 2.24 (1.22–4.11)
Non-digestive system 6 600 1.47 (1.24–1.74) 1.35 (0.86–2.13) 70 0.005
Respiratory system 1 113 0.5 (0.26–0.54) 0.5 (0.26–0.54)
NSCLC 1 113 0.5 (0.26–0.54) 0.5 (0.26–0.54)
Other system 5 487 1.59 (1.34–1.90) 1.61 (1.25–2.06) 15 0.32
BC 2 281 1.55 (1.29–1.87) 1.55 (1.29–1.87) 0 0.62
Osteosarcoma 1 84 2.93 (1.12–7.67) 2.93 (1.12–7.67)
retinoblastoma 1 60 2.90 (1.05–8.03) 2.90 (1.05–8.03)
ccRCC 1 62 0.77 (0.24–2.47) 0.77 (0.24–2.47)
Analysis method
 Univariate analysis 3 238 0.95 (0.66–1.37) 0.84 (0.41–1.75) 68 0.04
 Multivariate analysis 7 911 1.71 (1.47–2.02) 1.79 (1.47–2.18) 11 0.34
HR estimation method
 Indirectly 4 349 1.07 (0.76–1.52) 1.15 (0.52–2.56) 76 0.006
 Directly 6 802 1.69 (1.44–1.99) 1.69 (1.44–1.99) 0 0.49
number of patients
 more than 100 6 880 1.56 (1.33–1.82) 1.57 (1.07–2.31) 70 0.005
 less than 100 4 271 1.62 (1.11–2.35) 1.71 (1.01–2.90) 36 0.2
BANCR expression level
 high expression 8 976 1.68 (1.45–1.96) 1.71 (1.44–2.03) 6 0.38
 low expression 2 175 0.55 (0.31–0.96) 0.55 (0.31–0.96) 0 0.52
Quality scores
 Score = 9 8 973 1.54 (1.32–1.80) 1.61 (1.15–2.24) 64 0.007
 Score < 9 2 178 1.78 (1.04–3.06) 1.48 (0.53–4.11) 61 0.008
DFS 3 320 1.29 (0.91–1.82) 1.21 (0.33–4.41) 93 0.00001
RFS 1 216 1.53 (1.27–1.85) 1.53 (1.27–1.85)
  1. Note: BANCR BRAF-activated noncoding RNA; OS Overall survival; DFS: disease-free survival; PFS Progression-free survival; Random Random effects; Fixed Fixed effects; directly: HR was extracted directly from the primary articles; indirectly: HR was extracted indirectly from the primary articles; NSCLC Non-small cell lung cancer; HCC Hepatocellular carcinoma; CRC Colorectal cancer; BC Breast cancer; ccRCC Clear cell renal cell carcinoma; GC Gastric cancer; LNM Lymphatic node metastasis; DM Distant metastasis; HTS High tumor stage (III,IV);NA Not available; ESCC Esophagus cancer; directly: HR was extracted directly from article; OS Overall survival; DFS Disease free survival; RFS: recurrence free survival